Xintela: Biopharma developing stem cell therapy and targeted cancer therapy for diseases with high medical need
Innovative stem cell research for the future
Xintela conducts groundbreaking research in regenerative medicine and targeted cancer therapy, with stem cells at the core to treat severe diseases such as osteoarthritis and difficult-to-heal wounds.
Xintela’s drug development in both stem cell therapy and cancer therapy is based on a unique marker technology platform based on specific cell surface markers (integrins), which enables better precision and efficacy in treatments for both humans and animals. Through ongoing clinical studies, such as XSTEM for osteoarthritis, we accelerate from lab to patient.
With partnerships in the global life science industry, we position ourselves to revolutionize therapies – sustainably and patient-safely.
XSTEM against knee osteoarthritis
Xintela's Phase I/IIa study in Australia is testing XSTEM in patients with moderate knee osteoarthritis – recently initiated the final dose level to repair damaged cartilage and reduce pain.
XSTEM for venous leg ulcers
In a Phase I/IIa study, Xintela is collaborating with experts to treat difficult-to-heal venous leg ulcers with XSTEM, based on promising preclinical results for faster wound healing.
EQSTEM for horse joint diseases
EQSTEM shows strong preclinical results for the treatment of osteoarthritis and degenerative joint disease in horses, with potential for increased mobility and sustainable veterinary medicine.
Targeted cancer therapy
Our subsidiary Targinta is developing innovative cancer therapy based on integrin α10β1 markers, with targeted antibodies against severe forms such as triple-negative breast cancer and glioblastoma – for more effective treatments in the preclinical phase.
- Latest News
- Financial Reports
